Overview Safety Evaluation Study for Patients With Polycythemia Vera Status: Recruiting Trial end date: 2023-10-01 Target enrollment: Participant gender: Summary This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera Phase: Phase 1 Details Lead Sponsor: Perseus Proteomics Inc.